SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles.
Saved in:
| Title: | SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. |
|---|---|
| Authors: | Zhang, Ting1 (AUTHOR), Xu, Jianyan1 (AUTHOR), Yin, Junzhao1 (AUTHOR), Gao, Yun1 (AUTHOR), Zheng, Hanwen1 (AUTHOR), Fu, Beibei1 (AUTHOR), Sun, Jiakang1 (AUTHOR), Xu, Zhibin1 (AUTHOR), Tu, Shiwei1 (AUTHOR), Mao, Yuchang1 (AUTHOR), Wen, Weiyun1 (AUTHOR), Qu, Bolei1 (AUTHOR), You, Lingfeng1 (AUTHOR), Xue, Zhendong1 (AUTHOR), Sun, Xing2 (AUTHOR), Cao, Dan1 (AUTHOR), Feng, Jun1 (AUTHOR), Hu, Min1 (AUTHOR) min.hu@hengrui.com, He, Feng1 (AUTHOR) feng.he@hengrui.com |
| Source: | PLoS ONE. 6/26/2025, Vol. 20 Issue 6, p1-16. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 19326203 |
|---|---|
| DOI: | 10.1371/journal.pone.0326691 |
